Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2023 | The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies

In this video, Torsten Haferlach, MD, PhD, MLL Munich Leukemia Laboratory, Munich, Germany, discusses the value of whole genome sequencing (WGS) and whole transcriptome sequencing in diagnosing hematological malignancies. Prof. Haferlach believes that in the near future, once barriers to their implementation have been addressed, these techniques will be utilized in routine clinical practice for the diagnosis of leukemias, lymphomas, and other malignancies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

MLL Munich Leukemia Laboratory: Current Employment; Other: Equity Ownership.